Which of the following statements is correct?
After initiation of teriparatide, bone-formation markers increase at the same time as bone-resorption markers
Treatment with PTH/PTHrP analogs must be followed by the administration of an antiresorptive agent
Increases in spine BMD are usually greater in patients who have switched from bisphosphonates to teriparatide than in treatment-naive patients
When compared with teriparatide, abaloparatide shows a similar rate of bone formation and bone resorption
Teriparatide and abaloparatide bind to PTH type 2 receptor (PTH2R)
Teriparatide is made up of the last 34 amino acids of parathyroid hormone (PTH)
Teriparatide can be taken orally
Intermittent PTH administration is anabolic, but continuous infusion of PTH is catabolic
Teriparatide is not contraindicated in patients at known risks of osteosarcoma
Osteoclasts are rational anabolic therapeutic targets
Which of the following statements is NOT correct?
Intermittent PTH improves bone microarchitecture
Anabolic therapy is the treatment of choice for patients at very high risk of fracture
There is no biosimilar preparation of teriparatide
Intermittent PTH treatment increases periosteal perimeter of cortical bone
Intermittent PTH treatment increases porosity near the endocortical surface
What is the primary mechanism of action of PTH/PTHrP analogs in osteoporosis treatment?
They directly inhibit osteoclast activity
They promote calcium absorption in the intestines without affecting bone
They stimulate osteoblast function and bone formation
They act as calcium chelators, preventing bone resorption
They replace lost bone tissue through direct stem cell activation
What PTH/PTHrP analogs does NOT do?
They improve bone strength
They improve microarchitecture
They increase BMD
What is the recommended maximum duration of teriparatide therapy for osteoporosis?
6 months
1 year
2 years
5 years
Lifetime use is recommended